Loading stock…

NeoGenomics, Inc. (NEO) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

NeoGenomics, Inc.

NEOMarket cap $2.05BPrice $16.0

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

NeoGenomics runs specialized cancer testing labs that help doctors diagnose and monitor tumors at the genetic level. Oncologists nationwide rely on its lab results to pick the right treatment, making it a hidden backbone of precision cancer care.

In Bastion Portfolios?

52W Return+59%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+13%8

Revenue Forecast

Rev CAGR (1y)+11%6

Rev CAGR (3y)+10%7

Rev CAGR (5y)+9%7

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+90%10

EPS Growth Y+3+47%9

Quality

Margins

EBIT Margin-5%1

Net Income Margin-7%1

Free Cash Flow Margin-1%3

Debt

Net Debt/EBITDA9.21

Efficiency

ROE-6%2

ROA-4%1

Earnings Stability22

GEAR+VERY WEAK10

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)591

P/E Ratio (Forward 3y)311

P/BV2.65

EV Multiples

EV/EBITDA Fwd421

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-0.4%3

Dividend Yieldna–

Momentum

Short term

1 month return-9%3

3 month return+12%9

YTD return+36%9

Mid term

Price vs 52wHigh79%5

1 year return+74%10

Long term

3 year return+32%5

5 year return-62%1

Risk Shield

Price Risk

Beta1.23

Volatility54%3

Free Cash Flow

Free Cash Flow Margin-1%3

Free Cash Flow Yield-0.4%3

Quality

ROCE-3%1

Earnings Stability22

Net Debt/EBITDA9.21

02Growth

Is it actually growing, and how fast?

NEONeoGenomics

Revenue FY25$727M

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+90%10

EPS growth, FY28E+47%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 13%/yr over the last 3 years and is set to keep growing around 10%/yr.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE51 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return+12%9

YTD return+36%9

MID & LONG-TERM▾SCORE

% of 52-week high79%5

1-year return+74%10

3-year return+32%5

5-year return-62%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 74% over the past year, but 21% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+12%) and so far this year (+36%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+32% over three years and -62% over five), behind 70% of the market.

The stock is underperforming over the past month (-9%).

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on NeoGenomics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

NEONeoGenomics

Revenue FY25$727M

GROWTH RATING↗

STRONG69 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+11%6

Revenue, next 3Y, CAGR+10%7

Revenue, next 5Y, CAGR+9%7

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+90%10

EPS growth, FY28E+47%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 69% of companies worldwide.

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 10%/yr over the next 3 years, ahead of most of the market.7/10

Revenue grew 13%/yr over the last 3 years and is set to keep growing around 10%/yr.

The runway holds up: revenue is set to grow 9%/yr over five years.7/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE51 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-9%3

3-month return+12%9

YTD return+36%9

MID & LONG-TERM▾SCORE

% of 52-week high79%5

1-year return+74%10

3-year return+32%5

5-year return-62%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 74% over the past year, but 21% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+12%) and so far this year (+36%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+32% over three years and -62% over five), behind 70% of the market.

The stock is underperforming over the past month (-9%).

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on NeoGenomics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community